Search

Author/Creator Talal, A. H.

1. Absolute and relative contraindications to pegylated‐interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV‐infected, evaluated patients. Issue 4 (7th January 2013)

Authors:
Talal, A. H.; LaFleur, J.; Hoop, R.; Pandya, P.; Martin, P.; Jacobson, I.; Han, J.; Korner, E. J.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 37:Issue 4(2013)
Page Start:
473
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Commentary: absolute and relative contraindications to pegylated‐interferon or ribavirin in the US general patient population with chronic hepatitis C – authors' reply. Issue 5 (13th August 2013)

Authors:
Talal, A. H.; LaFleur, J.; Hoop, R. S.; Pandya, P.; Martin, P.; Jacobson, I. M.; Han, J.; Korner, E. J.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 38:Issue 5(2013)
Page Start:
554
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. Issue 11 (7th October 2013)

Authors:
Afdhal, N. H.; Zeuzem, S.; Schooley, R. T.; Thomas, D. L.; Ward, J. W.; Litwin, A. H.; Razavi, H.; Castera, L.; Poynard, T.; Muir, A.; Mehta, S. H.; Dee, L.; Graham, C.; Church, D. R.; Talal, A. H.; Sulkowski, M. S.; Jacobson, I. M.
Journal:
Journal of viral hepatitis
Issue:
Volume 20:Issue 11(2013)
Page Start:
745
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗